QM · rank #18 · 2026-07-21
SNT
GPW · PLN · $869M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +47.09% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $869M |
| Anchor (recent) Close on 2026-06-19 | $296.80 |
| Anchor (far) Close on 2025-06-20 | $201.78 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. manufactures proprietary radiopharmaceuticals, develops medical IT software, and distributes high-end diagnostic and therapeutic systems like da Vinci surgical robots in Central Europe.
Rationale
The strong quality-momentum signal is validated by high underlying ROE, robust recurring revenues, and strong revenue visibility underpinned by a 163 million PLN order backlog and CE-certified Edison system distribution.
Material risks
- 1Potential loss of exclusive distribution or sole-supplier rights for key high-end medical equipment like da Vinci robotic systems, which would immediately commoditize its core revenue engine.
- 2Inability of the newly spun-off Syn2bio to successfully secure partnering and licensing agreements to monetize its cardiotracer R&D pipeline.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.